263 related articles for article (PubMed ID: 37236760)
1. 20-Hydroxyeicosatetraenoic acid (20-HETE): Bioactions, receptors, vascular function, cardiometabolic disease and beyond.
Pascale JV; Wolf A; Kadish Y; Diegisser D; Kulaprathazhe MM; Yemane D; Ali S; Kim N; Baruch DE; Yahaya MAF; Dirice E; Adebesin AM; Falck JR; Schwartzman ML; Garcia V
Adv Pharmacol; 2023; 97():229-255. PubMed ID: 37236760
[TBL] [Abstract][Full Text] [Related]
2. 20-HETE Signals Through G-Protein-Coupled Receptor GPR75 (G
Garcia V; Gilani A; Shkolnik B; Pandey V; Zhang FF; Dakarapu R; Gandham SK; Reddy NR; Graves JP; Gruzdev A; Zeldin DC; Capdevila JH; Falck JR; Schwartzman ML
Circ Res; 2017 May; 120(11):1776-1788. PubMed ID: 28325781
[TBL] [Abstract][Full Text] [Related]
3. The CYP/20-HETE/GPR75 axis in hypertension.
Froogh G; Garcia V; Laniado Schwartzman M
Adv Pharmacol; 2022; 94():1-25. PubMed ID: 35659370
[TBL] [Abstract][Full Text] [Related]
4. CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid- and angiotensin II-dependent.
Sodhi K; Wu CC; Cheng J; Gotlinger K; Inoue K; Goli M; Falck JR; Abraham NG; Schwartzman ML
Hypertension; 2010 Nov; 56(5):871-8. PubMed ID: 20837888
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension.
Garcia V; Joseph G; Shkolnik B; Ding Y; Zhang FF; Gotlinger K; Falck JR; Dakarapu R; Capdevila JH; Bernstein KE; Schwartzman ML
Am J Physiol Regul Integr Comp Physiol; 2015 Jul; 309(1):R71-8. PubMed ID: 25924878
[TBL] [Abstract][Full Text] [Related]
6. Conflicting roles of 20-HETE in hypertension and renal end organ damage.
Zhang C; Booz GW; Yu Q; He X; Wang S; Fan F
Eur J Pharmacol; 2018 Aug; 833():190-200. PubMed ID: 29886242
[TBL] [Abstract][Full Text] [Related]
7. Uncovering the signalling, structure and function of the 20-HETE-GPR75 pairing: Identifying the chemokine CCL5 as a negative regulator of GPR75.
Pascale JV; Park EJ; Adebesin AM; Falck JR; Schwartzman ML; Garcia V
Br J Pharmacol; 2021 Sep; 178(18):3813-3828. PubMed ID: 33974269
[TBL] [Abstract][Full Text] [Related]
8. Blockade of 20-hydroxyeicosatetraenoic acid receptor lowers blood pressure and alters vascular function in mice with smooth muscle-specific overexpression of CYP4A12-20-HETE synthase.
Agostinucci K; Hutcheson R; Hossain S; Pascale JV; Villegas E; Zhang F; Adebesin AM; Falck JR; Gupte S; Garcia V; Schwartzman ML
J Hypertens; 2022 Mar; 40(3):498-511. PubMed ID: 35081581
[TBL] [Abstract][Full Text] [Related]
9. Induction of angiotensin-converting enzyme and activation of the renin-angiotensin system contribute to 20-hydroxyeicosatetraenoic acid-mediated endothelial dysfunction.
Cheng J; Garcia V; Ding Y; Wu CC; Thakar K; Falck JR; Ramu E; Schwartzman ML
Arterioscler Thromb Vasc Biol; 2012 Aug; 32(8):1917-24. PubMed ID: 22723444
[TBL] [Abstract][Full Text] [Related]
10. GPR75 receptor mediates 20-HETE-signaling and metastatic features of androgen-insensitive prostate cancer cells.
Cárdenas S; Colombero C; Panelo L; Dakarapu R; Falck JR; Costas MA; Nowicki S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Feb; 1865(2):158573. PubMed ID: 31760076
[TBL] [Abstract][Full Text] [Related]
11. Vascular actions of 20-HETE.
Hoopes SL; Garcia V; Edin ML; Schwartzman ML; Zeldin DC
Prostaglandins Other Lipid Mediat; 2015 Jul; 120():9-16. PubMed ID: 25813407
[TBL] [Abstract][Full Text] [Related]
12. Activation of GPR75 Signaling Pathway Contributes to the Effect of a 20-HETE Mimetic, 5,14-HEDGE, to Prevent Hypotensive and Tachycardic Responses to Lipopolysaccharide in a Rat Model of Septic Shock.
Tunctan B; Senol SP; Temiz-Resitoglu M; Yilmaz DE; Guden DS; Bahceli O; Horat MF; Sahan-Firat S; Sari AN; Falck JR; Anugu RR; Malik KU
J Cardiovasc Pharmacol; 2022 Aug; 80(2):276-293. PubMed ID: 35323151
[TBL] [Abstract][Full Text] [Related]
13. 20-Hydroxyeicosatetraenoic Acid (HETE)-dependent Hypertension in Human Cytochrome P450 (CYP) 4A11 Transgenic Mice: NORMALIZATION OF BLOOD PRESSURE BY SODIUM RESTRICTION, HYDROCHLOROTHIAZIDE, OR BLOCKADE OF THE TYPE 1 ANGIOTENSIN II RECEPTOR.
Savas Ü; Wei S; Hsu MH; Falck JR; Guengerich FP; Capdevila JH; Johnson EF
J Biol Chem; 2016 Aug; 291(32):16904-19. PubMed ID: 27298316
[TBL] [Abstract][Full Text] [Related]
14. Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.
Tunctan B; Korkmaz B; Sari AN; Kacan M; Unsal D; Serin MS; Buharalioglu CK; Sahan-Firat S; Cuez T; Schunck WH; Manthati VL; Falck JR; Malik KU
Nitric Oxide; 2013 Sep; 33():18-41. PubMed ID: 23684565
[TBL] [Abstract][Full Text] [Related]
15. 20-HETE in the regulation of vascular and cardiac function.
Rocic P; Schwartzman ML
Pharmacol Ther; 2018 Dec; 192():74-87. PubMed ID: 30048707
[TBL] [Abstract][Full Text] [Related]
16. 20-HETE contributes to ischemia-induced angiogenesis.
Chen L; Joseph G; Zhang FF; Nguyen H; Jiang H; Gotlinger KH; Falck JR; Yang J; Schwartzman ML; Guo AM
Vascul Pharmacol; 2016 Aug; 83():57-65. PubMed ID: 27084395
[TBL] [Abstract][Full Text] [Related]
17. 20-HETE induces remodeling of renal resistance arteries independent of blood pressure elevation in hypertension.
Ding Y; Wu CC; Garcia V; Dimitrova I; Weidenhammer A; Joseph G; Zhang F; Manthati VL; Falck JR; Capdevila JH; Schwartzman ML
Am J Physiol Renal Physiol; 2013 Sep; 305(5):F753-63. PubMed ID: 23825080
[TBL] [Abstract][Full Text] [Related]
18. Recent developments on the vascular effects of 20-hydroxyeicosatetraenoic acid.
Garcia V; Schwartzman ML
Curr Opin Nephrol Hypertens; 2017 Mar; 26(2):74-82. PubMed ID: 27906746
[TBL] [Abstract][Full Text] [Related]
19. The role of 20-HETE in cardiovascular diseases and its risk factors.
Waldman M; Peterson SJ; Arad M; Hochhauser E
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():108-17. PubMed ID: 27287720
[TBL] [Abstract][Full Text] [Related]
20. 20-HETE and blood pressure regulation: clinical implications.
Wu CC; Gupta T; Garcia V; Ding Y; Schwartzman ML
Cardiol Rev; 2014; 22(1):1-12. PubMed ID: 23584425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
